Preliminary Findings of Platelet-Rich Plasma-Induced Ameliorative Effect on Polycystic Ovarian Syndrome

Overview

Journal Cell J

Specialty Cell Biology

Date 2019 Jun 19

PMID 31210429

Citations 9

Authors

Samira Seyyed Anvari

G Holamreza Dehgan

Mazdak Razi

Affiliations

Soon will be listed here.

Abstract

Objective: Polycystic ovarian syndrome (PCOS) is characterized by hormonal imbalance, oxidative stress and chronic anovulation. The present study was designed to assess ameliorative effect of auto-locating platelet-rich plasma (PRP), as a novel method, for inhibiting PCOS-induced pathogenesis in experimentally-induced hyperandrogenic PCOS.

Materials And Methods: In this experimental study, 30 immature (21 days old) female rats were assigned into five groups, including control (sampled after 30 days with no treatment), 15 and 30 days PCOS-sole-induced as well as 15 and 30 days PRP auto-located PCOS-induced groups. Serum levels of estrogen, progesterone, androstenedione, testosterone, follicle stimulating hormone (FSH), luteinizing hormone (LH), ovarian total antioxidant capacity (TAC), malondialdehyde (MDA), glutathione peroxidase (GSH-px) and superoxide dismutase (SOD) were evaluated. Expression of estrogen receptor α (), β () and were assessed. Finally, the numbers of intact follicles per ovary and mRNA damage ratio were analyzed.

Results: PRP groups significantly (P<0.05) decreased serum levels of FSH, LH, testosterone and androstenedione and remarkably (P<0.05) increased estrogen and progesterone syntheses versus PCOS-sole groups. The PRP auto-located animals exhibited increased TAC, GSH-px and SOD levels, while they showed diminished MDA content (P<0.05) versus PCOS-sole groups. The PRP auto-located groups exhibited an elevated expression of and versus PCOS-sole groups. Moreover, PRP groups significantly (P<0.05) decreased expression and mRNA damage compared to PCOS-sole groups, and remarkably improved follicular growth.

Conclusion: PRP is able to regulate hormonal interaction, improve the ovarian antioxidant potential as well as folliculogenesis and its auto-location could be considered as a novel method to prevent/ameliorate PCOS-induced pathogenesis.

Citing Articles

A Retrospective Cohort Study Investigating the Effect of Intraovarian Platelet-Rich Plasma Therapy on the Oxidative State of Follicular Fluid in Women with Diminished Ovarian Reserve.

Mazloomi S, Tayebinia H, Farimani M, Ghorbani M Chonnam Med J. 2025; 61(1):46-51.

PMID: 39958271 PMC: 11821988. DOI: 10.4068/cmj.2025.61.1.46.

Ameliorative Effect of Combined Placenta-Derived Mesenchymal Stem Cells plus Platelet-rich Plasma on Polycystic Ovarian Model in Rats: A Biochemical and Histological Study.

Sarvestani M, Rajabzadeh A, Salimian M, Mazoochi T, Ghavipanjeh G Reprod Sci. 2025; 32(3):907-918.

PMID: 39856459 DOI: 10.1007/s43032-025-01791-0.

Oxidative stress and energy metabolism abnormalities in polycystic ovary syndrome: from mechanisms to therapeutic strategies.

Yan H, Wang L, Zhang G, Li N, Zhao Y, Liu J Reprod Biol Endocrinol. 2024; 22(1):159.

PMID: 39722030 PMC: 11670460. DOI: 10.1186/s12958-024-01337-0.

Platelet-rich plasma attenuates the UPEC-induced cystitis via inhibiting MMP-2,9 activities and downregulation of NGF and VEGF in Canis Lupus Familiaris model.

Abdelgalil A, Yassin A, Khattab M, Abdelnaby E, Marouf S, Farghali H Sci Rep. 2024; 14(1):13612.

PMID: 38871929 PMC: 11176177. DOI: 10.1038/s41598-024-63760-y.

Therapeutic roles of platelet-rich plasma to restore female reproductive and endocrine dysfunction.

Wang X, Li J, Lu W, Gao F, Zhang S, Li J Front Endocrinol (Lausanne). 2024; 15:1374382.

PMID: 38654928 PMC: 11035829. DOI: 10.3389/fendo.2024.1374382.

References

Darzynkiewicz Z, Bedner E, Li X, Gorczyca W, Melamed M . Laser-scanning cytometry: A new instrumentation with many applications. Exp Cell Res. 1999; 249(1):1-12. DOI: 10.1006/excr.1999.4477. View

Dupont S, Krust A, Gansmuller A, Dierich A, Chambon P, Mark M . Effect of single and compound knockouts of estrogen receptors alpha (ERalpha) and beta (ERbeta) on mouse reproductive phenotypes. Development. 2000; 127(19):4277-91. DOI: 10.1242/dev.127.19.4277. View

Margolis D, Kantor J, SANTANNA J, Strom B, Berlin J . Effectiveness of platelet releasate for the treatment of diabetic neuropathic foot ulcers. Diabetes Care. 2001; 24(3):483-8. DOI: 10.2337/diacare.24.3.483. View

Carreau S . Germ cells: a new source of estrogens in the male gonad. Mol Cell Endocrinol. 2001; 178(1-2):65-72. DOI: 10.1016/s0303-7207(01)00411-7. View

Bhanot S, Alex J . Current applications of platelet gels in facial plastic surgery. Facial Plast Surg. 2002; 18(1):27-33. DOI: 10.1055/s-2002-19824. View

Bose B, Balzarini M . Bone graft gel: autologous growth factors used with autograft bone for lumbar spine fusions. Adv Ther. 2002; 19(4):170-5. DOI: 10.1007/BF02848692. View

Wiren K, Chapman Evans A, Zhang X . Osteoblast differentiation influences androgen and estrogen receptor-alpha and -beta expression. J Endocrinol. 2002; 175(3):683-94. DOI: 10.1677/joe.0.1750683. View

Nandedkar T, Dharma S . Expression of bcl(xs) and c-myc in atretic follicles of mouse ovary. Reprod Biomed Online. 2003; 3(3):221-225. DOI: 10.1016/s1472-6483(10)62040-8. View

Pant N, Srivastava S . Testicular and spermatotoxic effects of quinalphos in rats. J Appl Toxicol. 2003; 23(4):271-4. DOI: 10.1002/jat.919. View

10.

. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2003; 19(1):41-7. DOI: 10.1093/humrep/deh098. View

11.

Carmina E, Koyama T, Chang L, Stanczyk F, Lobo R . Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome?. Am J Obstet Gynecol. 1992; 167(6):1807-12. DOI: 10.1016/0002-9378(92)91779-a. View

12.

Banaszewska B, Spaczynski R, Pelesz M, Pawelczyk L . Incidence of elevated LH/FSH ratio in polycystic ovary syndrome women with normo- and hyperinsulinemia. Rocz Akad Med Bialymst. 2004; 48:131-4. View

13.

LOWRY O, ROSEBROUGH N, FARR A, RANDALL R . Protein measurement with the Folin phenol reagent. J Biol Chem. 1951; 193(1):265-75. View

14.

Honnma H, Endo T, Henmi H, Nagasawa K, Baba T, Yamazaki K . Altered expression of Fas/Fas ligand/caspase 8 and membrane type 1-matrix metalloproteinase in atretic follicles within dehydroepiandrosterone-induced polycystic ovaries in rats. Apoptosis. 2006; 11(9):1525-33. DOI: 10.1007/s10495-006-9148-2. View

15.

Banaszewska B, Pawelczyk L, Spaczynski R, Dziura J, Duleba A . Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. J Clin Endocrinol Metab. 2006; 92(2):456-61. DOI: 10.1210/jc.2006-1988. View

16.

Fardoun R . The use of vitamin E in type 2 diabetes mellitus. Clin Exp Hypertens. 2007; 29(3):135-48. DOI: 10.1080/10641960701361601. View

17.

Hoffman B, Liebermann D . Apoptotic signaling by c-MYC. Oncogene. 2008; 27(50):6462-72. DOI: 10.1038/onc.2008.312. View

18.

Vrbikova J, Hainer V . Obesity and polycystic ovary syndrome. Obes Facts. 2010; 2(1):26-35. PMC: 6444522. DOI: 10.1159/000194971. View

19.

Yang Y, Qiao J, Li R, Li M . Is interleukin-18 associated with polycystic ovary syndrome?. Reprod Biol Endocrinol. 2011; 9:7. PMC: 3035581. DOI: 10.1186/1477-7827-9-7. View

20.

Goodarzi M, Dumesic D, Chazenbalk G, Azziz R . Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol. 2011; 7(4):219-31. DOI: 10.1038/nrendo.2010.217. View